Table 2.

Complete response (CR), time to complete response (TCR), and tumor progression rate at 315 days (TP 315) in treatment arms with alternate dosing/scheduling of lapatinib/trastuzumab in BT474 tumor xenografts.

	Full L+T §	T	L	1/2L+1/2T	L+T 42 days	L+T 14days	L+T 14 days on/off
N (mice)	13	19	13	15	15	15	14
Median TCR	35	63	70	49	42	35	35
P*	Ref	0.008	0.0003	0.03	0.58	0.72	0.46
CR (%)	100	89	77	93	100	80	100
TP 315 (%)	0	16	46	13	28	60	14
P*	Ref	0.13	0.009	0.18	0.05	0.001	0.17

^*P value of generalized Wilcoxon test comparing other treatment groups to reference group (Ref).

^§T: trastuzumab, L: lapatinib